Clinical trial of methoxy polyethylene glycol-epoetin beta (MIRCERA) for renal anemia with chronic heart failure

Clinical trial of methoxy polyethylene glycol-epoetin beta (MIRCERA) for renal anemia with chronic heart failure - Clinical trial of methoxy polyethylene glycol-epoetin beta (MIRCERA) for renal anemia with chronic heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025419

Enrollment

Registered

2016-12-26

Start date

2015-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia with chronic heart failure

Interventions

MIRCERA (50~150 U/m)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Renal anemia with chronic heart failure Patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: Patients from whom informed consent was not obtained

Design outcomes

Primary

Measure	Time frame
Hemoglobin	—

Secondary

Measure	Time frame
1) BNPm ANP 2) NYHA class 3) cardiac function by UCG (EF, LVDd, LVMI) 4) serum Cr, eGFR 5) hs-CRP 6) cystatin C 7) ox-LDL 8) Urinary Albumin 9) renin, angiotensin-II, aldosterone 10) side effect	—

Countries

Japan

Contacts

Public ContactMitsue Akiyama

Sekino Laboratory Department of Research

skn-np@sekino-hospital.com03-3986-5501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026